1. Home
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Nasal Polyposis - Market Insight, Epidemiology And Market Forecast - 2032

Nasal Polyposis - Market Insight, Epidemiology And Market Forecast - 2032

  • August 2022
  • 161 pages
  • ID: 6316441
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Nasal Polyposis - Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the Nasal Polyposis, historical and forecasted epidemiology as well as the Nasal Polyposis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The Nasal Polyposis market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted 7MM Nasal Polyposis market size from 2019 to 2032. The Report also covers current Nasal Polyposis treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2019–2032

Nasal Polyposis Disease Understanding and Treatment Algorithm

Nasal Polyposis Overview
Nasal Polyposis/Nasal Polyposis are small, benign drop-like growths appearing in the mucosa (lining tissues) of the nose and may block the nasal passageway. Nasal Polyposis tends to be present on both sides of the nasal cavity. Small Nasal Polyposis may not reflect any symptoms, but the larger growths or groups of Nasal Polyposis can block the nasal passages or lead to breathing problems, a lost sense of smell, and frequent infections. One-sided Nasal Polyposis may need to be investigated further as they might be malignant nasal or sinus tumors.
Nasal Polyposis are a subgroup of chronic rhinosinusitis. Chronic rhinosinusitis is a condition where the nasal cavity and sinuses are inflamed for more than 4 to 12 weeks. Patients suffering from chronic rhinosinusitis condition can be progressed into chronic rhinosinusitis with NP (CRSwNP), and chronic rhinosinusitis without NP (CRSsNP). Only a portion of chronic rhinosinusitis will develop Nasal Polyposis. CRSwNP is a potentially debilitating condition in adults that are characterized by inflammation of the nose and paranasal sinuses with the presence of Nasal Polyposis.
People with a history of chronic sinus infections, allergic rhinitis, asthma, cystic fibrosis, sensitivity to NSAIDs like ibuprofen and aspirin, and Churg–Strauss syndrome are more prone to getting Nasal Polyposis. Patients suffering from NP may experience chronic nasal congestion, running nose, postnasal drip, reduced sense of smell and taste, difficulty in breathing, pressure in the face or forehead area, snoring, sleep apnea, and others.
Nasal Polyposis Diagnosis
The diagnosis of Nasal Polyposis is based on a combination of history, physical examination, and often a sinus CT scan. The history of nasal congestion and loss of smell points to Nasal Polyposis. Nasal examination often by nasal endoscopy confirms the diagnosis of Nasal Polyposis and distinguishes patients with CRSwNP from patients with CRSwNP. A sinus CT scan is helpful because it documents the extent of sinus disease.
Continued in the report…..

Nasal Polyposis Treatment
The standard treatment for Nasal Polyposis includes a combination of pharmacological and surgical approaches depending on individual case assessment. In general, patients are treated medically in the primary care setting before considering surgical procedures. Treatment aims to eliminate or significantly reduce the size of the Nasal Polyposis resulting in relief of nasal obstruction, improvement in sinus drainage, and restoration of olfaction and taste. Treatment of any accompanying rhinitis symptoms may also be required. With both treatments, recurrences are common, particularly in patients with asthma who are twice as likely to develop recurrence compared with nonasthmatics.
The current treatment of Nasal Polyposis includes corticosteroids (intranasal and systemic) in addition to anti-histamines, antibiotics, and NSAIDs which are given depending on the patient’s need. When drug treatment doesn’t shrink or eliminate Nasal Polyposis, endoscopic surgery is recommended to remove polyps and correct problems with your sinuses that make them prone to inflammation and the development of polyps. After surgery, corticosteroid nasal spray is recommended to prevent the recurrence of NP along with biologics. Over the years the US FDA has approved various corticosteroids and biologics for the treatment of Nasal Polyposis which includes XHANCE (fluticasone propionate), SINUVA (mometasone furoate) Sinus Implant, PROPEL (mometasone furoate), DUPIXENT (dupilumab), and others.
Continued in the report…..

Nasal Polyposis Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by prevalent cases of chronic rhinosinusitis, diagnosed prevalent cases of chronic rhinosinusitis, diagnosed prevalent cases of Nasal Polyposis, and gender-specific diagnosed prevalent cases of Nasal Polyposis, the scenario of Nasal Polyposis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Key Findings
• The total prevalent cases of chronic rhinosinusitis in the 7MM were found to be approximately 69,550,461 cases in 2021. The prevalent cases of chronic rhinosinusitis are expected to rise by 2032.
• Among all the 7MM countries, the United States accounted for the highest diagnosed prevalent cases (approximately 8,691,874 cases) of chronic rhinosinusitis in 2021.
• In 2021, the total reported diagnosed prevalent cases of Nasal Polyposis in the 7MM countries were approximately 4,358,603 cases which are expected to increase by 2032.
• In 2021, Germany accounted for the highest number of Nasal Polyposis diagnosed prevalent cases (approximately 617,716 cases), followed by the United Kingdom (approximately 435,157 cases) among EU-5 countries. In contrast, Spain accounted for the lowest number of Nasal Polyposis diagnosed prevalent cases in EU-5.
• As per the analysis, in Japan, most of the diagnosed prevalent cases of Nasal Polyposis were reported in males. In 2021, there were approximately 111,545 diagnosed prevalent cases of Nasal Polyposis among males and approximately 91,264 cases among females in Japan.

Nasal Polyposis Epidemiology
The epidemiology segment also provides the Nasal Polyposis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Nasal Polyposis Drug Chapters
The drug chapter segment of the Nasal Polyposis report encloses the detailed analysis of Nasal Polyposis marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Nasal Polyposis clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.
Nasal Polyposis Marketed Drugs
DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals
DUPIXENT is an interleukin-4 receptor alpha antagonist, indicated as an add-on maintenance treatment in adult patients with inadequately controlled CRSwNP. Patients with comorbid CRSwNP and asthma are often more difficult to treat, so it is encouraging that DUPIXENT, which targets key drivers of Type 2 inflammation, may address both conditions in these patients.
The drug was originally approved in 2017 for patients 12 and older with eczema that is not controlled adequately by topical therapies or when those therapies are not advisable. In 2018, DUPIXENT was approved as an add-on maintenance treatment for patients 12 years and older with moderate-to-severe eosinophilic asthma or with oral corticosteroid-dependent asthma.
XOLAIR (omalizumab): Hoffmann-La Roche/Novartis
XOLAIR is the first biologic for the treatment of Nasal Polyposis that targets and blocks IgE, a key driver of inflammation. Omalizumab is a recombinant DNA-derived humanized IgG1? monoclonal antibody that selectively binds to human IgE. The drug is administered as a SC injection and is available in prefilled syringes and vials. The injection form is a lyophilized, white, sterile powder in a 150 mg single-dose vial without preservatives, and prefilled Syringe is available in 75 mg and 150 mg.
The FDA’s approval for Nasal Polyposis was based on results from the Phase III POLYP 1 and POLYP 2 trials. Before this approval, XOLAIR had 17 years of patient experience since its initial approval for allergic asthma, then for chronic spontaneous urticarial and chronic idiopathic urticaria (CIU)
Products detail in the report…
List of products to be continued in the report…

Nasal Polyposis Emerging Drugs
FASENRA (benralizumab): AstraZeneca
FASENRA, being developed by AstraZeneca, is a monoclonal antibody that binds directly to Interleukin-5 receptor alpha (IL-5R?) on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis. FASENRA targets seven diseases beyond respiratory disease. Based on the results of OSTRO and ORCHID Phase III trials of FASENRA AstraZeneca submitted a supplemental Biologics License Application (sBLA) to the US FDA. In March 2022, the US FDA issued a CRL to the sBLA and requested additional clinical data for the same. AstraZeneca in response to the CRL is conducting a second Phase III trial, the ORCHID to evaluate the efficacy and safety of FASENRA compared to placebo in patients with eosinophilic CRSwNP.
TEZSPIRE (tezepelumab): AstraZeneca/Amgen
AstraZeneca is developing TEZSPIRE as a potential human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP). TSLP is an epithelial-derived cytokine produced in response to airborne stimuli, such as allergens, viruses, and diesel exhaust. It plays a key role in the initiation and persistence of airway inflammation by activating multiple downstream inflammatory pathways. TSLP expression is elevated in the airways of patients with asthma compared with healthy individuals and in nasal polyp tissue from patients with CRSwNP compared with healthy sinus tissue or from patients with CRS without Nasal Polyposis. The presence of TSLP correlates with the number of eosinophils in nasal polyp tissue, and the activity of TSLP in polyp tissue is believed to be sufficient to trigger an inflammatory response. In patients with asthma, the level of TSLP expression in airway tissue has been shown to correlate with airway obstruction and disease severity.
The company is currently conducting Phase III trials to evaluate the efficacy and safety of tezepelumab in adults with severe, CRSwNP. This trial is based on positive results of tezepelumab from the PATHWAY and NAVIGATOR trials in patients with severe, uncontrolled asthma and comorbid Nasal Polyposis.
Products detail in the report…
List of products to be continued in the report…

Nasal Polyposis Market Outlook
Nasal Polyposis represents a chronic inflammatory condition of unknown etiology. It is often associated with systemic diseases and is characterized by nasal obstruction, reduction in sense of smell, infection, and impaired quality of life. In the recent decade, endoscopy has enhanced the diagnosis and management of Nasal Polyposis, which ultimately increases the diagnosis rate of the disease. In the management, the initial approach is medical management which includes the use of corticosteroids (nasal spray, topical and oral) and antibiotics, etc.
In many patients, Nasal Polyposis returns if the irritation, allergy, infection, or inflammation continues. Antihistamines and decongestants may help with allergy symptoms that may lead to the development of nasal polyps, but these medications do not directly address the Nasal Polyposis themselves.
Once patients have failed or not responded to initial treatment, then surgical procedure is an option. The purpose of surgery is to restore nasal physiology by making the nose free from nasal polyps and allowing drainage of infected sinuses. Most of the time, after surgery, patients are recommended to take medical therapy for preventing recurrence.
Over the last 5 years, biologics are started to come into the market for both the pool (not responding to initial treatment and recurrent cases from surgery). Now, only severe NP patients are preferred to take biologics. As with the launch of more biologics in the upcoming years, the ratio of patients opting for surgery might reduce due to the excellent efficacy of biologics and also less possibility of recurrence of the disease.

Key Findings
• The market size of Nasal Polyposis in seven major markets was approximately USD 1,531.9 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 9.05% for the study period (2019–2032).
• The expected launch of potential therapies may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Nasal Polyposis.
• The United States accounts for the largest market size for Nasal Polyposis, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
• Upcoming therapies such as CM301, FASENRA, and others have the potential to create a significant positive shift in the Nasal Polyposis market size.
• Among EU5 countries, Germany had the highest market size with approximately USD 132.2 million in 2021.

The United States Market Outlook
This section provides the total Nasal Polyposis market size and market size by therapies in the United States.

The EU-5 Market Outlook
The total Nasal Polyposis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook
The total Nasal Polyposis market size and market size by therapies in Japan are provided.

Nasal Polyposis Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the Nasal Polyposis market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Nasal Polyposis market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, and the reasons behind the maximal use of new drugs and allow, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Nasal Polyposis Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stages and also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities
The report covers detailed information on collaborations, acquisitions, mergers, licensing, and patent details for Nasal Polyposis emerging therapies.
Reimbursement Scenario in Nasal Polyposis
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis
We perform competitively and market Intelligence analysis of the Nasal Polyposis market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
• The report covers the descriptive overview of Nasal Polyposis, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
• Comprehensive insight has been provided into Nasal Polyposis epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Nasal Polyposis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Nasal Polyposis market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Nasal Polyposis market.

Report Highlights
• The robust pipeline with novel MOA and oral ROA and increasing diagnosed prevalence will positively drive the Nasal Polyposis market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Nasal Polyposis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Nasal Polyposis. The launch of emerging therapies will significantly impact the Nasal Polyposis market.
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Nasal Polyposis Report Insights
• Patient Population
• Therapeutic Approaches
• Nasal Polyposis Pipeline Analysis
• Nasal Polyposis Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Nasal Polyposis Report Key Strengths
• 11-Years Forecast
• The 7MM Coverage
• Nasal Polyposis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market

• Drugs Uptake

Nasal Polyposis Report Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• SWOT analysis

Key Questions

Market Insights:
• What was the Nasal Polyposis market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Nasal Polyposis total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
• What are the key findings of the market across the 7MM and which country will have the largest Nasal Polyposis market size during the forecast period (2022–2032)?
• At what CAGR, the Nasal Polyposis market is expected to grow at the 7MM level during the forecast period (2022–2032)?
• What would be the Nasal Polyposis market outlook across the 7MM during the forecast period (2022–2032)?
• What would be the Nasal Polyposis market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:
• What are the disease risk, burdens, and unmet needs of Nasal Polyposis?
• What is the historical Nasal Polyposis patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Nasal Polyposis at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Nasal Polyposis?
• Out of the above-mentioned countries, which country would have the highest population of Nasal Polyposis during the forecast period (2022–2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
• What are the current options for the treatment of Nasal Polyposis along with the approved therapy?
• What are the current treatment guidelines for the treatment of Nasal Polyposis in the US and Europe?
• What are the Nasal Polyposis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Nasal Polyposis?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Nasal Polyposis?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Nasal Polyposis therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Nasal Polyposis and their status?
• What are the key designations that have been granted for the emerging therapies for Nasal Polyposis?
• What is the 7MM historical and forecasted market for Nasal Polyposis?

Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving Nasal Polyposis.
• To understand the future market competition in the Nasal Polyposis market and an Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Nasal Polyposis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Nasal Polyposis market.
• To understand the future market competition in the Nasal Polyposis market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • $ 3500
  • September 2022
  • 89 pages

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the ...

  • World
  • United States
  • Biotechnology
  • Respiratory Disease
  • Industry analysis
  • HIV AIDS Prevalence
  • Prescription Drug Sales

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on